FREE BCACP Clinical Literature Interpretation Questions and Answers

Question 1

A pharmacist reviews a randomized controlled trial comparing a new lipid-lowering agent to placebo. The primary endpoint was major adverse cardiovascular events (MACE). The event rate in the placebo group was 12% and in the new agent group was 8%. What is the number needed to treat (NNT) to prevent one MACE?

Accepted Answer

25

Answer

The Number Needed to Treat (NNT) is the reciprocal of the Absolute Risk Reduction (ARR). First, calculate the ARR: ARR = (Event Rate in Control Group) - (Event Rate in Treatment Group) = 12% - 8% = 4% or 0.04. Then, calculate the NNT: NNT = 1 / ARR = 1 / 0.04 = 25. This means 25 patients need to be treated with the new agent to prevent one additional MACE compared to placebo.

Question 2

A clinical trial evaluates a new medication for stroke prevention in patients with atrial fibrillation. The results for the primary outcome of ischemic stroke are reported as a Hazard Ratio (HR) of 0.80 with a 95% Confidence Interval (CI) of 0.65 to 1.05. Which of the following is the most accurate interpretation of this finding?

Accepted Answer

The result is not statistically significant.

Answer

For a ratio metric like a Hazard Ratio (HR), Relative Risk (RR), or Odds Ratio (OR), the null value (representing no difference between groups) is 1.0. A 95% Confidence Interval indicates a range where the true effect is likely to lie. Because this 95% CI (0.65 to 1.05) crosses 1.0, we cannot exclude the possibility of no difference. Therefore, the result is not statistically significant at the p<0.05 level.

Question 3

Researchers wish to determine if exposure to a certain workplace chemical is associated with the development of a rare form of cancer. They identify a group of individuals with the cancer (cases) and a similar group without the cancer (controls). They then look back in time, using work history records, to determine the rate of chemical exposure in each group. Which study design does this describe?

Accepted Answer

Case-Control Study

Answer

This describes a case-control study. This design starts by identifying individuals with the outcome of interest (cases) and a comparable group without the outcome (controls). It then looks retrospectively to compare the frequency of exposure to a risk factor in both groups. A prospective cohort study would start with exposed and unexposed groups and follow them forward in time to see who develops the disease.

Question 4

A large, multicenter randomized controlled trial is analyzed using the intention-to-treat (ITT) principle. What is the primary advantage of using an ITT analysis?

Accepted Answer

It preserves the benefits of randomization and reflects a more realistic measure of treatment effectiveness.

Answer

The intention-to-treat (ITT) principle analyzes all participants in the group to which they were originally randomized, regardless of whether they received the treatment or adhered to the protocol. The primary advantage is that it maintains the prognostic balance created by the initial randomization, preventing biases that can occur when patients drop out or are non-adherent. This approach provides a more pragmatic and real-world estimate of the treatment's effectiveness.

Question 5

A clinical trial for a new heart failure medication reports a statistically significant reduction in its primary composite endpoint of 'cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.' An analysis of the individual components reveals the benefit was driven almost exclusively by a reduction in urgent heart failure visits, with no significant difference in CV death or hospitalizations. What is the most appropriate clinical interpretation?

Accepted Answer

The benefit of the drug is primarily related to reducing less severe events like urgent heart failure visits.

Answer

When evaluating a composite endpoint, it is crucial to examine the individual components to understand the true effect of the intervention. A significant result for the composite does not automatically apply to all its components. In this case, the benefit was driven by the softest, least severe endpoint, so the most accurate interpretation is that the drug's main effect is on reducing urgent HF visits, not necessarily on the more severe outcomes of hospitalization or death.

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

FREE BCACP Clinical Literature Interpretation Questions and Answers